Treatment of Tinea Capitis
Oral Antifungal Therapy is Absolutely Required
Tinea capitis requires oral antifungal therapy—topical treatment alone is completely ineffective and must never be used as monotherapy. 1 Topical antifungals cannot penetrate hair follicles adequately to eradicate the infection. 1
Start Treatment Immediately Without Waiting for Culture Results
- Begin empirical oral antifungal therapy immediately if clinical signs are present (scale, lymphadenopathy, alopecia, or kerion), while awaiting mycological confirmation. 1
- Do not delay treatment waiting for culture results when the clinical presentation is evident. 1
- Ideally confirm diagnosis through potassium hydroxide preparation or culture to identify the causative organism, but this should not delay initiation of therapy. 2
First-Line Agent Selection Based on Causative Organism
For Trichophyton Species (Including T. tonsurans):
Terbinafine is superior and the preferred first-line agent for Trichophyton infections. 1
- Dosing by weight: 1
- Less than 20 kg: 62.5 mg daily
- 20-40 kg: 125 mg daily
- Over 40 kg: 250 mg daily
- Duration: 2-4 weeks 1
- Terbinafine has demonstrated 94% efficacy for Trichophyton species with excellent tolerability. 3
For Microsporum Species (Including M. canis):
Griseofulvin is more effective and the preferred first-line agent for Microsporum infections. 1
- Dosing by weight: 1
- Less than 50 kg: 15-20 mg/kg/day
- Over 50 kg: 1 g/day
- Duration: 6-8 weeks 1
- The FDA label confirms treatment periods of 4-6 weeks for tinea capitis, though current guidelines recommend longer durations for Microsporum. 2
When Organism is Unknown or Mixed:
Itraconazole has activity against both Trichophyton and Microsporum species and serves as a reasonable empiric choice. 1
- Dosing: 50-100 mg daily for 4 weeks, or 5 mg/kg/day for 2-4 weeks 1
- Itraconazole achieved 87% mycological cure rates in clinical trials. 4
- Important drug interactions exist with warfarin, certain antihistamines, antipsychotics, midazolam, digoxin, and simvastatin. 5
Critical Treatment Endpoint: Mycological Cure, Not Clinical Cure
The endpoint of treatment is mycological cure documented by negative microscopy and culture—not clinical appearance alone. 1
- Repeat mycology sampling until clearance is documented. 1
- Clinical improvement alone is insufficient to stop therapy, as clinical relapse will occur if the organism is not completely eradicated. 1, 2
- If clinical improvement is seen but mycology remains positive, continue current therapy for an additional 2-4 weeks. 1
Management of Treatment Failure
When treatment fails, assess systematically: 1
- Non-compliance with medication regimen
- Suboptimal drug absorption (consider taking griseofulvin with fatty foods)
- Organism resistance to the selected agent
- Reinfection from untreated contacts or contaminated fomites
If no clinical improvement is seen, switch agents: 1
- From terbinafine to griseofulvin for suspected Microsporum
- From griseofulvin to terbinafine for Trichophyton
- Consider itraconazole as an alternative
Essential Adjunctive Measures to Prevent Reinfection
Screen all family members and close contacts for infection, as more than 50% may be affected with T. tonsurans. 1
- Treat asymptomatic carriers with high spore loads systemically. 1
- Clean all fomites (hairbrushes, combs, towels, bedding) with disinfectant or 2% sodium hypochlorite solution. 1
- Consider sporicidal shampoos such as selenium sulfide to aid in removing adherent scales and decrease spread. 6
Critical Pitfalls to Avoid
- Never use topical antifungals alone—they do not penetrate hair follicles adequately. 1
- Never use terbinafine for Microsporum infections—it has inferior efficacy compared to griseofulvin. 1
- Never stop treatment based on clinical appearance alone—mycological cure must be confirmed. 1
- Never forget to screen household contacts, especially with T. tonsurans infections. 1
- Do not use griseofulvin as first-line for Trichophyton when terbinafine is available, as it requires longer treatment duration and has lower cure rates. 5